Your eyes are rebuilding right now
Every day, your retina renews the structures that help you see. That process depends on rare VLC-PUFAs ordinary eye supplements do not meaningfully deliver.
The retina is built for constant renewal
From morning light to late-night screens, your photoreceptors are always working — processing, shedding, rebuilding. This is not occasional repair. It is daily maintenance. And daily maintenance depends on the right materials.
10% of the photoreceptor outer segment renews every single day.
-
The full structure rebuilds completely in just 10 days.
-
Every day, your retina needs specialized lipid support.
10% of the photoreceptor outer segment renews every single day.
The lipid ordinary eye nutrition forgot
Most eye supplements focus on antioxidants, pigments, or common omega-3s. All of those have a place. But your retina also contains a rarer class of omega-3 lipids called VLC-PUFAs — very-long-chain polyunsaturated fatty acids.
These lipids are longer, more specialized, and concentrated in photoreceptor-rich retinal tissue. They are part of what your eyes rebuild with.
Fish oil starts the omega-3 story. ELOVL goes further.
Standard Omega-3s
DHA and EPA helped define modern nutritional science. But retinal lipid biology does not stop at DHA.
Retinal VLC-PUFAs
VLC-PUFAs are longer, rarer omega-3s found in the retina and present in standard fish oil only in trace amounts.
ELOVL Vision Lipids brings both together
A next-generation omega-3 supplement designed to provide familiar DHA/EPA support plus concentrated VLC-PUFAs for retinal lipid maintenance
The pathway behind retinal VLC-PUFAs
VLC-PUFAs are not something most diets meaningfully provide. Your body makes them through lipid-elongation pathways involving enzymes called ELOVL2 and ELOVL4. But aging changes that pathway.
Over time, the system that helps create these rare retinal lipids may become less efficient — right as your retina continues its daily demand for renewal.
The problem is not that your eyes stop needing VLC-PUFAs. It is that aging may make them harder to supply.
Known for decades. Available now.
Scientists have studied VLC-PUFAs for decades. The challenge was never whether these molecules mattered. The challenge was access. They were rare. Difficult to isolate. Expensive to produce. Locked inside laboratories.
Then EPAX solved the concentration problem at commercial scale. For the first time, concentrated VLC-PUFAs could move from retinal lipid research into everyday nutritional support.
That is why ELOVL exists now.
Built from retinal lipid science
This is not a trend. It is a new application of a research story that has been building for decades.
VLC-PUFAs have been identified in photoreceptor-rich retinal tissue.
Human tissue studies have observed lower VLC-PUFA levels in aging-related retinal samples.
Preclinical studies have shown that supplied VLC-PUFAs can reach ocular tissue and influence retinal biology.
Not a new discovery. A newly accessible one.
1967
Your eyes never stop rebuilding
Scientists discover that photoreceptors shed and renew their outer tips continuously — 10% replaced every day, the full structure rebuilt every 10 days. The most actively renewing tissue in the human body.
Young RW, Journal of Cell Biology
1980s
A unique class of fat found almost exclusively in the eyes and brain.
Researchers identify VLC-PUFAs concentrated in the eye and brain — almost nowhere else in the body. The question at the time: what are they doing there?
2001
Children born without VLC-PUFAs lose their vision
Inherited mutations blocking VLC-PUFA production cause severe, progressive vision loss beginning in childhood. The molecule is confirmed as essential.
Zhang et al., Nature Genetics
2013
The largest eye nutrition trial ever run finds no benefit from fish oil.
The AREDS2 trial — thousands of patients, years of follow-up — finds zero benefit from omega-3 fish oil for age-related vision loss. The mechanism of failure would only be understood later.
AREDS2 Research Group, JAMA
2020
EPAX develops the first commercial VLC-PUFA concentrate.
EPAX achieves concentrated VLC-PUFAs at commercial scale for the first time, making it possible to deliver meaningful amounts in a daily supplement.
2024
ELOVL Vision Lipids launches.
The first consumer product built around concentrated VLC-PUFAs becomes available. Decades of retinal lipid research, in two softgels a day.
2025
Something that had never been shown before in eye science.
Scientists gave aged animals VLC-PUFAs — the molecule aging takes away — and looked inside their eyes. Within five days, molecular markers of aging had shifted. The tissue looked younger. Standard fish oil produced no comparable effect in the same study.
Gao et al., Science Translational Medicine
The finished molecule. Not just a precursor.
ELOVL Vision Lipids delivers concentrated VLC-PUFAs from EPAX EVOLVE 05 — the world's first commercial VLC-PUFA concentrate. Two softgels daily. Built for retinal lipid maintenance.
Your retina rebuilds every day. Give it what ordinary supplements leave out.